ATE240733T1 - Kombination von 5-ht wiederaufnahme-inhibitoren und h5-ht 1b antagonisten oder partiellen agonisten - Google Patents

Kombination von 5-ht wiederaufnahme-inhibitoren und h5-ht 1b antagonisten oder partiellen agonisten

Info

Publication number
ATE240733T1
ATE240733T1 AT98944375T AT98944375T ATE240733T1 AT E240733 T1 ATE240733 T1 AT E240733T1 AT 98944375 T AT98944375 T AT 98944375T AT 98944375 T AT98944375 T AT 98944375T AT E240733 T1 ATE240733 T1 AT E240733T1
Authority
AT
Austria
Prior art keywords
rupup
antagonists
inhibitors
combination
partial agonists
Prior art date
Application number
AT98944375T
Other languages
English (en)
Inventor
Stefan Berg
Svante Ross
Seth-Olov Thorberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE240733T1 publication Critical patent/ATE240733T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Replacement Of Web Rolls (AREA)
  • Winding, Rewinding, Material Storage Devices (AREA)
AT98944375T 1997-09-18 1998-09-09 Kombination von 5-ht wiederaufnahme-inhibitoren und h5-ht 1b antagonisten oder partiellen agonisten ATE240733T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703375A SE9703375D0 (sv) 1997-09-18 1997-09-18 A new combination
PCT/SE1998/001601 WO1999013877A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Publications (1)

Publication Number Publication Date
ATE240733T1 true ATE240733T1 (de) 2003-06-15

Family

ID=20408295

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98944375T ATE240733T1 (de) 1997-09-18 1998-09-09 Kombination von 5-ht wiederaufnahme-inhibitoren und h5-ht 1b antagonisten oder partiellen agonisten

Country Status (29)

Country Link
US (1) US6159971A (de)
EP (1) EP1014985B1 (de)
JP (1) JP2001516718A (de)
KR (1) KR20010024076A (de)
CN (1) CN1195519C (de)
AR (1) AR015448A1 (de)
AT (1) ATE240733T1 (de)
AU (1) AU752722B2 (de)
BR (1) BR9812088A (de)
CA (1) CA2302382A1 (de)
DE (1) DE69814882T2 (de)
DK (1) DK1014985T3 (de)
EE (1) EE04141B1 (de)
ES (1) ES2200370T3 (de)
HU (1) HUP0200602A3 (de)
IL (1) IL134776A0 (de)
IS (1) IS5406A (de)
MY (1) MY116280A (de)
NO (1) NO20001399L (de)
NZ (1) NZ503171A (de)
PL (1) PL339371A1 (de)
PT (1) PT1014985E (de)
RU (1) RU2214824C2 (de)
SE (1) SE9703375D0 (de)
SK (1) SK2852000A3 (de)
TR (1) TR200000727T2 (de)
TW (1) TW589183B (de)
WO (1) WO1999013877A1 (de)
ZA (1) ZA987817B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
CZ20033267A3 (en) * 2001-05-01 2004-06-16 H. Lundbeck A/S The use of enantiomeric pure escitalopram
DK1408976T5 (da) * 2001-07-20 2011-01-10 Psychogenics Inc Behandling af ADHD (Attention deficit hyperactivity disorder)
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
AR047553A1 (es) 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
KR100511288B1 (ko) * 2003-11-14 2005-08-31 엘지전자 주식회사 4대의 압축기를 구비한 공기조화기의 실외기
WO2006091725A1 (en) * 2005-02-23 2006-08-31 The Silvan S. Tomkins Institute Treatment of anhedonia
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
FR2890862B1 (fr) * 2005-09-19 2008-01-25 Sanofi Aventis Sa Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
EP2056797A2 (de) 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH System mit kontrollierter freisetzung und verfahren zu seiner herstellung
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination

Also Published As

Publication number Publication date
HUP0200602A2 (hu) 2002-07-29
AU9193098A (en) 1999-04-05
WO1999013877A1 (en) 1999-03-25
DE69814882D1 (de) 2003-06-26
TW589183B (en) 2004-06-01
EP1014985A1 (de) 2000-07-05
BR9812088A (pt) 2000-09-26
JP2001516718A (ja) 2001-10-02
ZA987817B (en) 1999-03-18
IS5406A (is) 2000-03-15
CN1278729A (zh) 2001-01-03
KR20010024076A (ko) 2001-03-26
CA2302382A1 (en) 1999-03-25
RU2214824C2 (ru) 2003-10-27
CN1195519C (zh) 2005-04-06
TR200000727T2 (tr) 2000-09-21
EP1014985B1 (de) 2003-05-21
PL339371A1 (en) 2000-12-18
SK2852000A3 (en) 2000-09-12
HK1032739A1 (en) 2001-08-03
EE200000141A (et) 2001-02-15
EE04141B1 (et) 2003-10-15
US6159971A (en) 2000-12-12
NO20001399L (no) 2000-05-10
PT1014985E (pt) 2003-10-31
NZ503171A (en) 2002-02-01
AR015448A1 (es) 2001-05-02
IL134776A0 (en) 2001-04-30
DK1014985T3 (da) 2003-09-15
HUP0200602A3 (en) 2003-04-28
NO20001399D0 (no) 2000-03-17
DE69814882T2 (de) 2004-05-19
ES2200370T3 (es) 2004-03-01
AU752722B2 (en) 2002-09-26
SE9703375D0 (sv) 1997-09-18
MY116280A (en) 2003-12-31

Similar Documents

Publication Publication Date Title
ATE240733T1 (de) Kombination von 5-ht wiederaufnahme-inhibitoren und h5-ht 1b antagonisten oder partiellen agonisten
NO975245D0 (no) Heterocykluser som inhibitorer av laukocyttadhesjon og VLA-4-antagonister
ID17316A (id) Komposisi aditif untuk pembawa bahan bermanfaat dan komposisi batang yang mengandung aditif tersebut
BR9706968A (pt) Uso de antagonistas de alfa-ppar e gama-ppar para o tratamento de sindrome x
FI20085256L (fi) Retrovirusperäisten proteaasi-inhibiittoreiden yhdistelmä
DE59709342D1 (de) Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE69835020D1 (de) Plasmabrenner und verwendungsverfahren dieses plasmabrenners
DE59709383D1 (de) 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE69704877D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
ATE408607T1 (de) Substituierte benzensulfonamid-derivate als wirkstoff-vorläufer von cox-2 inhibitoren
MA26668A1 (fr) ACTIVATEURS DE hPPARy ET hPPARa
DE69632610D1 (de) Zementzusammensetzungen und ihre Verwendung zur Zementierung von Ölbohrlöchern oder ähnlichen
EP1047426A4 (de) Verwendung von methylnaltrexon und verwandten verbindungen
PT796855E (pt) Inibicao da reabsorcao nos ossos e antagonistas de vitronectina
DE69430662D1 (de) Zusammensetzungen von fluorkohlenwasserstoffen und kohlenwasserstoffen
ID22650A (id) Penggunaan penghambat-penghambat lipase usus lambung
NO20000268D0 (no) Anvendelse av Lactobacillus for reduksjon av fibrinogen nivå
DK0736525T3 (da) Benzonitriler som 5-HT-agonister og -antagonister
PT927183E (pt) Inibidores espirociclicos de metaloproteases
DE60001735D1 (de) 1-aminotriazolo 4,3-a chinazolin-5-one und/oder -thione inhibitoren von phosphodiesterasen iv
ATE270889T1 (de) Monoaminoxidase inhibitor- und h5-ht 1 beta antagonist oder partiellagonist enthaltende mischung
DE69418203D1 (de) Zementiermittel und ihre verwendung
DE60009888D1 (de) Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen
DE69531048D1 (de) Verwendung von steroidsulphatase-hemmern
FI952458L (fi) Dimetyylibentsofuraanien ja dimetyylibentsopyraanien käyttö 5-HT3-antagonisteina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1014985

Country of ref document: EP

REN Ceased due to non-payment of the annual fee